Ramy Sedhom, MD, FASCO

Imagine 4 new anticancer drugs Pallituzumab, Geriatriximab, Symptomab, & Exercizumab hit the market. They should dominate the plenary sessions at ASCO & command billion-dollar revenue. But they don't because they're nonpharmacologic & shame on us. Read our opinion piece in @JCO_ASCO ascopubs.org/doi/full/10.12…

Congrats @laurasenamd for publishing the definitive study on IDH1-altered prostate cancers. This is a distinct molecular subtype of PCa with novel therapeutic implications (vorasidenib?). @neerajaiims @VanAllenLab @nikolausschultz europeanurology.com/action/showPdf…

Helpful reflections on the POSITIVE trial - summary - premenopausal hormone receptor–positive patients could be safely treated for their cancer while pursuing family goals ascopost.com/issues/april-2…

“Speak to your children as if they are the wisest, kindest, most beautiful and magical humans on earth, for what they believe is what they will become.”

New study: LLMs identified geriatric assessment domains in EHR notes of older adults with advanced cancer with low false evidence rates @JGeriOnc @WilliamDale_MD sciencedirect.com/science/articl…

We have the evidence We have the tools We have the guidelines But adoption is still low As @WilliamDale_MD noted: the next challenge isn’t discovery, it’s implementation @PallOncCoP @realbowtiedoc @JamesFanWu @FionnualaCrowle @Chaosdyna @jillfeldman4 @DarcyBurbage @ramsedhom

Alliance Trial - duloxetine does not prevent oxaliplatin induced peripheral neuropathy ascopubs.org/doi/10.1200/OA…

Communication is an intervention. For older adults w/ cancer, the 1st visit & major turning points — progression, hospitalization, decline — are mission critical. journals.sagepub.com/doi/10.1177/10…

@DrHBurstein @ASCO @DanaFarber Great work by the oncology care team, patients and families to prioritize clinical trials

Of the 5 plenary talks @ASCO, two are from @DanaFarber. You know, in case you were wondering where in the world you should go for the best, most advanced cancer care.

Outside my usual scope of cancer - but what a beautiful message in this podcast from ⁦@PennMedicine⁩ Memory Center podcasts.apple.com/us/podcast/age…

💩 First randomized placebo-controlled FMT trial in any solid tumor. The donor? A long-term complete ICI responder. TACITO (Porcari, Ciccarese et al.) randomized 45 tx-naive mRCC pts on pembro/axitinib to donor vs placebo FMT. Primary 12-mo PFS rate not met — but median PFS significantly favored donor FMT, and donor bacteria engraftment linked to durable outcomes. 🔑 Not practice-changing yet — but the right design and huge effort. bit.ly/4cI3Nhv #RCC #KidneyCancer #FMT #Microbiome #TACITO #ICI #GUonc #JournalClub

SONIA trial @JAMAOnc : In HR+/HER2− advanced #BreastCancer, first-line CDK4/6i did not improve OS vs delayed use (47.9 vs 48.1 mo; HR 0.91), despite modest PFS gain. Higher toxicity without QoL benefit. jamanetwork.com/journals/jamao… @OncoAlert #bcsm

I also want to highlight the third author of this NEJM paper is Alex Spira - a community oncologist! Love to see innovation in clinical trial access & enrollment

Proud to be the recipient of the Hasting Center Physician award for exceptional care for patients near the end of life. Care of the person & relief of suffering are the foundation of cancer care cunniffdixon.org/foundation-new…

Congratulations to our own @ramsedhom, who has received the 2026 Hastings Center Cunniff-Dixon Early Career Physician Award. @PC3Innovation @PrincetonHealth spr.ly/6010B6Nwne

@DrRishabhOnco @brunolarvol Can you share with me a scenario where a person with triple negative breast cancer wouldn’t get chemotherapy? It is used in curative setting for all and in incurable setting is standard after first line

TNBC is no longer a chemo disease. This 1 algorithm shows the shift: 👉 ADCs + biomarkers are now driving frontline decisions. 🧬 Metastatic TNBC - how to think today PD-L1 ≥10 • Pembro + chemo • OR Pembro + SG PD-L1 <10 • SG or Dato-DXd now competing with chemo BRCA-mut • PARP inhibitors HER2-low • T-DXd option Later lines • ADC sequencing • Biomarker-directed therapy 🧠 Paradigm shift ❌ Before: one-size chemo ✅ Now: IO + ADCs + PARPi + precision oncology ⚠️ What matters next Not just “which drug” 👉 but “what sequence” Topo-1 ADCs → real cross-resistance concern 🎯 Takeaway Advanced TNBC has entered the ADC era. Smart sequencing will define outcomes. 🔖 📖 Full paper in comment ⬇️ #OncoTwitter #MedTwitter #TNBC #BreastCancer @OncoAlert @myesmo @esmo_open @JCOPO_ASCO

Doing my caregiver training modules led by @NickOdomPhD_RN @DocApplebaum - this data is something we often take for granted, but important to remember in our routine care of patients/families

Love this editorial @LindaBosserman calling out the grey in hormone replacement therapy after breast cancer, and the importance of shared decision making ascopubs.org/doi/full/10.12…

Really excited for this gerionc care delivery trial through our Cancer & Aging lab @PC3Innovation @efratdotan sciencedirect.com/science/articl…

Much touted AI scribes freed up 15 min per day, allowed 0.5 more pt visits per week, and no change in at-home work by physicians. Certainly far less than transformative. jamanetwork.com/journals/jama/…